scholarly journals Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country

2016 ◽  
Vol 49 (1) ◽  
pp. 1601967 ◽  
Author(s):  
Arshad Javaid ◽  
Nafees Ahmad ◽  
Amer Hayat Khan ◽  
Zubair Shaheen
Keyword(s):  
World Health Organization ◽  
Multidrug Resistant ◽  
World Health ◽  
High Burden ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
The World ◽  
Health Organization

World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?

2017 ◽  
Vol 21 (12) ◽  
pp. 1211-1213 ◽  
Author(s):  
V. Cox ◽  
J. Furin
Keyword(s):  
World Health Organization ◽  
Safety Data ◽  
Evaluation Process ◽  
Multidrug Resistant ◽  
World Health ◽  
Efficacy And Safety ◽  
Assessment Development ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Health Organization

The World Health Organization uses a Grading of Recommendations Assessment, Development, and Evaluation process to make recommendations for treating multidrug-resistant tuberculosis. Even with this standardized approach, there have been discrepancies between recommendations for newer drugs such as bedaquiline and delamanid and the shorter regimen. This may be because newer drugs are novel chemical entities and may merit closer scrutiny. Here, we explore the problematic nature of this supposition, arguing that although the newer drugs have been used in fewer individuals, they may have more robust efficacy and safety data than many of the second-line drugs used in the shorter regimen.

Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique

2019 ◽  
Vol 69 (10) ◽  
pp. 1809-1811 ◽  
Author(s):  
Mathieu Bastard ◽  
Lucas Molfino ◽  
Cláudia Mutaquiha ◽  
Miriam Arago Galindo ◽  
Pereira Zindoga ◽  
...  
Keyword(s):  
Multidrug Resistant ◽  
World Health ◽  
Injectable Drug ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
The World ◽  
Standardized Treatment ◽  
Mdr Tb ◽  
Small Cohort ◽  
Health Organization

Abstract Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.

scholarly journals World Health Organization reports highest rates of drug-resistant tuberculosis to date

2008 ◽  
Vol 13 (12) ◽  
pp. 11-12 ◽  
Author(s):  
Collective Editorial team
Keyword(s):  
Drug Resistance ◽  
World Health Organization ◽  
Multidrug Resistant ◽  
World Health ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Fourth Report ◽  
The World ◽  
Health Organization

On 26 February 2008, the World Health Organization (WHO) published its fourth report on the global situation regarding drug resistance in tuberculosis (TB). The report, based on information collected between 2002 and 2006 on 90,000 TB patients in 81 countries, found that 5.3% of the nine million new cases of TB each year are multidrug-resistant (MDR). This is the highest rate yet recorded.

Sign in / Sign up

Export Citation Format

Share Document